Marc van Dijk

Company: MiNK Therapeutics

Job title: Chief Scientific Officer

Seminars:

Assessing Techniques to Improve the TME For Therapeutic Discovery & Development 9:00 am

• Identifying the specific challenges associated with modelling MDS and their impact on translatability to the clinic • Presenting findings from NRASD12/BCL-2 mouse models of HR-MDS/AML demonstrating the ability to overcome resistance to Venetoclax, a BCL-2 inhibitor, by utilizing a Mek inhibitor • Presenting recent findings from the newly established RAS/p53R172H model of AML, highlighting…Read more

day: Conference Day One